Last reviewed · How we verify
Gamma Interferon 1b
Gamma Interferon 1b (IFN-γ-1b) activates macrophages and enhances immune cell function to boost innate and adaptive immunity.
Gamma Interferon 1b is an investigational immunomodulatory agent with multiple ongoing clinical trials for various conditions, including fungal infections, cancer, and genetic disorders. Despite no FDA approval, it shows promise in Phase 2 studies for candidemia and mycosis fungoides.
At a glance
| Generic name | Gamma Interferon 1b |
|---|---|
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Drug class | Cytokine; Interferon |
| Target | Interferon-gamma receptor (IFNGR) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
IFN-γ-1b is a recombinant cytokine that binds to interferon-gamma receptors on immune cells, particularly macrophages, enhancing their antimicrobial and antitumor activity. It increases expression of MHC molecules and activates natural killer cells and T cells, strengthening both innate and adaptive immune responses. This mechanism makes it useful in conditions characterized by impaired immune function or chronic infections.
Approved indications
- Chronic granulomatous disease (CGD)
- Severe osteopetrosis
Common side effects
- Fever
- Headache
- Fatigue
- Myalgia
- Injection site reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: